Show simple item record

dc.contributor.authorPreuss, Ulrich
dc.contributor.authorRalston, Stephen J
dc.contributor.authorBaldursson, Gisli
dc.contributor.authorFalissard, Bruno
dc.contributor.authorLorenzo, Maria J
dc.contributor.authorRodrigues Pereira, Rob
dc.contributor.authorVlasveld, Laurens
dc.contributor.authorCoghill, David
dc.date.accessioned2007-01-22T09:40:22Z
dc.date.available2007-01-22T09:40:22Z
dc.date.issued2006-12-01
dc.date.submitted2007-01-22
dc.identifier.citationEur Child Adolesc Psychiatry 2006, 15 Suppl 1:i4-i14en
dc.identifier.issn1018-8827
dc.identifier.pmid17177015
dc.identifier.doi10.1007/s00787-006-1002-0
dc.identifier.otherPSY12
dc.identifier.urihttp://hdl.handle.net/2336/7659
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractOBJECTIVE : To describe the methodology and to present the baseline findings of the Attention-deficit/hyperactivity Disorder Observational Research in Europe (ADORE) study, the primary objective of which is to describe the relationship between treatment regimen prescribed and quality of life of children with ADHD in actual practice. METHODS : In this 2-year prospective observational study, data on diagnosis, prescribed treatment and outcomes of ADHD were collected at seven time points by paediatricians and child psychiatrists on 1,573 children recruited in 10 European countries. The data presented here from the 1,478 patients included in the analyses describe the baseline condition, initial treatment regimen prescribed and quality of life of families with children with ADHD. RESULTS : Patients had a mean age of 9.0 years (SD 2.5) and 84% were male. Physicians diagnoses were made using DSM-IV (43 %), ICD-10 (32%) and both DSM-IV and ICD-10 (12 %). Mean age of awareness of a problem was 5.1 years, suggesting an average delay of approximately 4 years between awareness and diagnosis of ADHD. Baseline ADHD rating scale scores (physicianrated) indicated moderate to severe ADHD. Parent-rated SDQ scores were in agreement and suggested significant levels of co-existing problems. CGI-S, CGAS and CHIPCE scores also indicated significant impairment. Patients were offered the following treatments after the initial assessment: pharmacotherapy (25 %), psychotherapy (19 %), combination of pharmacotherapy and psychotherapy (25 %), other therapy (10 %) and no treatment (21 %). CONCLUSION : The ADORE study shows that ADHD is similarly recognised across 10 European countries and that the children are significantly impaired across a wide range of domains. In this respect, they resemble children described in previous ADHD samples.
dc.language.isoenen
dc.publisherDr. Dietrich Steinkopff Verlagen
dc.relation.urlhttp://www.metapress.com/content/325183725576t20q/en
dc.subject.meshAttention Deficit Disorder with Hyperactivityen
dc.subject.meshChilden
dc.subject.meshEuropeen
dc.subject.meshQuality of Lifeen
dc.subject.meshPubMed - in processen
dc.titleStudy design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE studyen
dc.typeArticleen
dc.identifier.journalEuropean child & adolescent psychiatryen
dc.format.digYES
html.description.abstractOBJECTIVE : To describe the methodology and to present the baseline findings of the Attention-deficit/hyperactivity Disorder Observational Research in Europe (ADORE) study, the primary objective of which is to describe the relationship between treatment regimen prescribed and quality of life of children with ADHD in actual practice. METHODS : In this 2-year prospective observational study, data on diagnosis, prescribed treatment and outcomes of ADHD were collected at seven time points by paediatricians and child psychiatrists on 1,573 children recruited in 10 European countries. The data presented here from the 1,478 patients included in the analyses describe the baseline condition, initial treatment regimen prescribed and quality of life of families with children with ADHD. RESULTS : Patients had a mean age of 9.0 years (SD 2.5) and 84% were male. Physicians diagnoses were made using DSM-IV (43 %), ICD-10 (32%) and both DSM-IV and ICD-10 (12 %). Mean age of awareness of a problem was 5.1 years, suggesting an average delay of approximately 4 years between awareness and diagnosis of ADHD. Baseline ADHD rating scale scores (physicianrated) indicated moderate to severe ADHD. Parent-rated SDQ scores were in agreement and suggested significant levels of co-existing problems. CGI-S, CGAS and CHIPCE scores also indicated significant impairment. Patients were offered the following treatments after the initial assessment: pharmacotherapy (25 %), psychotherapy (19 %), combination of pharmacotherapy and psychotherapy (25 %), other therapy (10 %) and no treatment (21 %). CONCLUSION : The ADORE study shows that ADHD is similarly recognised across 10 European countries and that the children are significantly impaired across a wide range of domains. In this respect, they resemble children described in previous ADHD samples.


This item appears in the following Collection(s)

Show simple item record